A study conducted in Alberta, Canada, found that self-administered subcutaneous immunoglobulin G (SCIg) therapy is considerably less expensive than clinic-administered intravenous immunoglobulin ...

Aim: To report the interesting case of a patient with common variable immune deficiency disease who demonstrated varied responses to intravenous (IV) and subcutaneous (SC) immunoglobulin (Ig ...

The prior authorization was denied. What’s more, in an unusual move, the insurer declined to allow a “peer-to-peer” review of ...

Takeda Canada Inc. (Takeda) is pleased to announce that Héma-Québec has added HyQvia®– (normal immunoglobulin [human] 10% and ...

UCB, a global biopharmaceutical company, today announced the CHMP (Committee for Medicinal Products for Human Use) has issued a positive opinion for the self-administration of RYSTIGGO® ...

(Takeda) is pleased to announce that Héma-Québec has added HyQvia ® – (normal immunoglobulin [human] 10% and recombinant human hyaluronidase solution for subcutaneous infusion) as a ...

Takeda Canada Inc., the Canadian organization of Takeda Pharmaceutical Co. Ltd. (TAK) announced Wednesday that non-profit ...

(Takeda) is pleased to announce that Héma-Québec has added HyQvia®– (normal immunoglobulin [human] 10% and recombinant human hyaluronidase solution for subcutaneous infusion) as a replacement ...

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that the European Commission has asked the Committee ...

The Food and Drug Administration has approved Omvoh (mirikizumab-mrkz) for the treatment of moderately to severely active Crohn disease in adults.